Health utility scores of colorectal cancer based on societal preference in Japan

Quality of Life Research

Volumn 18, Issue 8, 2009, Pages 1095-1103

  Shiroiwa, Takeru ^a   Fukuda, Takashi ^a   Tsutani, Kiichiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Colorectal neoplasms; FOLFOX; Quality adjusted life years; Standard gamble; Time trade off; XELOX

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; DEOXYCYTIDINE; PLATINUM COMPLEX;

ABSENCE OF SIDE EFFECTS; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; CANCER STAGING; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GROUPS BY AGE; HAND FOOT SYNDROME; HEALTH STATUS; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NAUSEA; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SCORING SYSTEM; SEX DIFFERENCE; STOMA; STOMATITIS; STRUCTURED QUESTIONNAIRE; TREATMENT RESPONSE; VOMITING; ADAPTIVE BEHAVIOR; AGE; ANALOGS AND DERIVATIVES; ATTITUDE TO HEALTH; COLORECTAL NEOPLASMS; EPIDEMIOLOGY; HEALTH STATUS INDICATOR; HEALTH SURVEY; MENTAL STRESS; MIDDLE AGED; MORTALITY; PATIENT SATISFACTION; PERCEPTION; QUALITY OF LIFE; QUESTIONNAIRE; STATISTICS;

ADAPTATION, PSYCHOLOGICAL; ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS INDICATORS; HEALTH SURVEYS; HUMANS; JAPAN; LEUCOVORIN; MALE; MIDDLE AGED; ORGANOPLATINUM COMPOUNDS; PATIENT SATISFACTION; QUALITY OF LIFE; QUESTIONNAIRES; SEX FACTORS; SOCIAL PERCEPTION; STATISTICS AS TOPIC; STRESS, PSYCHOLOGICAL;

EID: 70349230822     PISSN: 09629343     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11136-009-9513-z     Document Type: Article

References (31)

1. Ministry of Health, Labor and Welfare. (2007). Population Survey Report [in Japanese].
2. Center for Cancer Control and Information Services, National Cancer Center, Japan. (2007). Regional Cancer Records and Estimated National Figures [in Japanese].
3. M Buyse P Thirion RW Carlson T Burzykowski G Molenberghs, et al. 2000 Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: A meta-analysis. Meta-analysis group in cancer Lancet 356 9227 373 378 10972369 10.1016/S0140-6736(00)02528-9 1:CAS:528:DC%2BD3cXls1Cksr4%3D
4. LB Saltz JV Cox C Blanke LS Rosen L Fehrenbacher, et al. 2000 Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group New England Journal of Medicine 343 13 905 914 11006366 10.1056/NEJM200009283431302 1:CAS:528:DC%2BD3cXntFOkt7Y%3D (Pubitemid 30727802)
5. JY Douillard D Cunningham AD Roth M Navarro RD James, et al. 2000 Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial Lancet 355 9209 1041 1047 10744089 10.1016/S0140-6736(00)02034-1 1:CAS:528:DC%2BD3cXisFOnsb4%3D
6. C Tournigand T Andre E Achille G Lledo M Flesh, et al. 2004 FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study Journal of Clinical Oncology 22 2 229 237 14657227 10.1200/JCO.2004.05.113 1:CAS:528:DC%2BD2cXpsVKit7w%3D (Pubitemid 41095086)
7. A de Gramont A Figer M Seymour M Homerin A Hmissi, et al. 2000 Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer Journal of Clinical Oncology 18 16 2938 2947 10944126
8. R Porschen HT Arkenau S Kubicka R Greil T Seufferlein, et al. 2007 Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: A final report of the AIO colorectal study group Journal of Clinical Oncology 25 27 4217 4223 17548840 10.1200/JCO.2006.09.2684 1:CAS:528:DC%2BD2sXhtFyis7vK (Pubitemid 47548561)
9. E Diaz-Rubio J Tabernero A Gomez-Espana B Massuti J Sastre, et al. 2007 Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: Final report of the Spanish cooperative group for the treatment of digestive tumors trial Journal of Clinical Oncology 25 27 4224 4230 17548839 10.1200/JCO.2006.09.8467 1:CAS:528:DC%2BD2sXhtFyis7vL (Pubitemid 47548562)
10. J Cassidy S Clarke E Diaz-Rubio W Scheithauer A Figer, et al. 2008 Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer Journal of Clinical Oncology 26 12 2006 2012 18421053 10.1200/JCO.2007.14.9898 1:CAS:528:DC%2BD1cXlvFaqs7s%3D
11. LB Saltz S Clarke E Diaz-Rubio W Scheithauer A Figer, et al. 2008 Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study Journal of Clinical Oncology 26 12 2013 2019 18421054 10.1200/JCO.2007.14.9930 1:CAS:528:DC%2BD1cXlvFaqs7g%3D
12. ML Rothenberg JV Cox C Butts M Navarro YJ Bang, et al. 2008 Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: A randomized phase III noninferiority study Annals of Oncology 19 10 1720 1726 18550577 10.1093/annonc/mdn370 1:STN:280:DC%2BD1cnhslOgug%3D%3D
13. A Tsuchiya S Ikeda N Ikegami S Nishimura I Sakai, et al. 2002 Estimating an EQ-5D population value set: The case of Japan Health Economics 11 4 341 353 12007165 10.1002/hec.673 (Pubitemid 34578418)
14. GW Torrance W Furlong D Feeny M Boyle 1995 Multi-attribute preference functions. Health utilities index Pharmacoeconomics 7 6 503 520 10155336 10.2165/00019053-199507060-00005 1:STN:280:DyaK28%2Fksl2jug%3D%3D
15. The EuroQol Group 1990 EuroQol-a new facility for the measurement of health-related quality of life Health Policy 16 3 199 208 10.1016/0168-8510(90) 90421-9
16. J Brazier T Usherwood R Harper K Thomas 1998 Deriving a preference-based single index from the UK SF-36 Health Survey Journal of Clinical Epidemiology 51 11 1115 1128 9817129 10.1016/S0895-4356(98)00103-6 1:STN:280: DyaK1M%2Fjt1Siuw%3D%3D (Pubitemid 28527167)
17. J Brazier J Roberts M Deverill 2002 The estimation of a preference-based measure of health from the SF-36 Journal of Health Economics 21 2 271 292 11939242 10.1016/S0167-6296(01)00130-8 (Pubitemid 34143147)
18. DF Cella DS Tulsky G Gray B Sarafian E Linn, et al. 1993 The functional assessment of cancer therapy scale: Development and validation of the general measure Journal of Clinical Oncology 11 3 570 579 8445433 1:STN:280: DyaK3s7oslKqsQ%3D%3D
19. NK Aaronson S Ahmedzai B Bergman M Bullinger A Cull, et al. 1993 The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology Journal of the National Cancer Institute 85 5 365 376 8433390 10.1093/jnci/85.5.365 1:STN:280:DyaK3s7msVarsQ%3D%3D
20. GW Torrance 1986 Measurement of health state utilities for economic appraisal Journal of Health Economics 5 1 1 30 10311607 10.1016/0167-6296(86) 90020-2 1:STN:280:DyaL283otVOltQ%3D%3D (Pubitemid 16098443)
21. A Lloyd B Nafees J Narewska S Dewilde J Watkins 2006 Health state utilities for metastatic breast cancer British Journal of Cancer 95 6 683 690 16967055 10.1038/sj.bjc.6603326 1:STN:280:DC%2BD28rktVGhsQ%3D%3D (Pubitemid 44373482)
22. RJ Milne KH Heaton-Brown P Hansen D Thomas V Harvey, et al. 2006 Quality-of-life valuations of advanced breast cancer by New Zealand women Pharmacoeconomics 24 3 281 292 16519549 10.2165/00019053-200624030-00007 (Pubitemid 43374379)
23. M Lidgren N Wilking B Jonsson C Rehnberg 2007 Health related quality of life in different states of breast cancer Quality of Life Research 16 6 1073 1081 17468943 10.1007/s11136-007-9202-8 (Pubitemid 47174889)
24. ST Stewart L Lenert V Bhatnagar RM Kaplan 2005 Utilities for prostate cancer health states in men aged 60 and older Medical Care 43 4 347 355 15778638 10.1097/01.mlr.0000156862.33341.45 (Pubitemid 40515624)
25. S Doyle A Lloyd M Walker 2008 Health state utility scores in advanced non-small cell lung cancer Lung Cancer 62 3 374 380 18467000 10.1016/j.lungcan.2008.03.019
26. B Nafees M Stafford S Gavriel S Bhalla J Watkins 2008 Health state utilities for non small cell lung cancer Health and Quality of Life Outcomes 6 84 18939982 10.1186/1477-7525-6-84
27. Gold, M., Siegel, J., Russell, L., & Weinstein, M. (1996). Cost-effectiveness in health and medicine. Oxford: Oxford University Press.
28. Ministry of Education, Culture, Sports, Science and Technology. (2008). Labor force survey [in Japanese].
29. SD Ramsey MR Andersen R Etzioni C Moinpour S Peacock, et al. 2000 Quality of life in survivors of colorectal carcinoma Cancer 88 6 1294 1303 10717609 10.1002/(SICI)1097-0142(20000315)88:6<1294::AID-CNCR4>3.0.CO;2-M 1:STN:280:DC%2BD3c7otlGjuw%3D%3D (Pubitemid 30155164)
30. TR Wilson DJ Alexander P Kind 2006 Measurement of health-related quality of life in the early follow-up of colon and rectal cancer Diseases of the Colon and Rectum 49 11 1692 1702 17041750 10.1007/s10350-006-0709-9 (Pubitemid 44800486)
31. CY Ko M Maggard EH Livingston 2003 Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: A nationwide, population-based assessment Journal of Surgical Research 114 1 1 5 13678691 10.1016/S0022-4804(03)00167-7 (Pubitemid 37108668)